|
KBTBD7 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 4.73343586548935E-12 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
6.02107252944961E-12 |
| Normal-vs-Stage2 |
2.20630000002942E-06 |
| Normal-vs-Stage3 |
1.89637194836223E-12 |
| Normal-vs-Stage4 |
8.45989944764369E-14 |
| Stage1-vs-Stage2 |
8.849800E-02 |
| Stage1-vs-Stage3 |
1.144200E-01 |
| Stage1-vs-Stage4 |
2.615600E-02 |
| Stage2-vs-Stage3 |
1.485830E-02 |
| Stage2-vs-Stage4 |
5.557500E-03 |
| Stage3-vs-Stage4 |
4.663400E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.02091685000505E-12 |
| Normal-vs-AfricanAmerican |
5.83479997651182E-09 |
| Normal-vs-Asian |
1.97829530534932E-11 |
| Caucasian-vs-AfricanAmerican |
6.778800E-01 |
| Caucasian-vs-Asian |
9.274200E-01 |
| AfricanAmerican-vs-Asian |
7.467200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
5.51447776331315E-12 |
| Normal-vs-Female |
3.95594668134436E-12 |
| Male-vs-Female |
7.662000E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
3.59756668899536E-12 |
| Normal-vs-Age(41-60Yrs) |
1.15090159624742E-11 |
| Normal-vs-Age(61-80Yrs) |
4.05409039672122E-12 |
| Normal-vs-Age(81-100Yrs) |
3.368900E-04 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
6.452400E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.172400E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
6.045000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.182000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
5.325600E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
6.150400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
5.567900E-04 |
| Classical-VS-Follicular |
1.321200E-01 |
| Classical-VS-Other |
3.477400E-01 |
| Classical-VS-Normal |
1.62809765669181E-11 |
| Tall-VS-Follicular |
1.447150E-04 |
| Tall-VS-Other |
7.712400E-01 |
| Tall-VS-Normal |
1.64124269730337E-12 |
| Follicular-VS-Other |
1.985620E-01 |
| Follicular-VS-Normal |
2.63269994693616E-09 |
| Other-VS-Normal |
3.987500E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.19519974315108E-11 |
| Normal-vs-N1 |
9.2148511043888E-15 |
| N0-vs-N1 |
6.018900E-04 |
|
|
